Tag Archives: Novo

ADA: Novo Nordisk’s oral semaglutide posts another heart safety win

SAN FRANCISCO—Novo Nordisk may have already submitted its approval application for its oral GLP-1 drug semaglutide, but the deluge of positive data hasn’t stopped. Tuesday at the American Diabetes Association annual meeting, the Danish drugmaker rolled out cardiovascular outcomes results showing that the its wannabe blockbuster didn’t hurt cardiovascular safety in high-risk Type 2 diabetes… Read More »